Fractyl Health Inc (GUTS) Stock Analysis
Verdict: AVOID
Nasdaq delisting notices and clinical trial litigation compound a $47.1M cash runway burning $19M quarterly, driving extreme downside risk.
Investment score: 17/100
Analysis as of
Is Fractyl Health Inc stock worth reviewing? AI model thesis
Fractyl Health faces existential balance sheet strain, a Nasdaq delisting determination, and extensive litigation, making the stock unviable for standard investment portfolios.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Fractyl Health Inc opportunities and risks
What speaks for GUTS
- Potential FDA De Novo Submission for Revita
What speaks against GUTS
- Critical Cash Runway and Impending Equity Dilution
Frequently asked questions about Fractyl Health Inc (GUTS)
Is GUTS stock a good investment?
The cached TradeMates AI model rates Fractyl Health Inc as AVOID with an investment score of 17/100. Fractyl Health faces existential balance sheet strain, a Nasdaq delisting determination, and extensive litigation, making the stock unviable for standard investment portfolios. This is algorithmic model output, not personal investment advice.
Is GUTS stock a buy?
The TradeMates model verdict for GUTS is AVOID with an investment score of 17/100. Treat this as a model signal to review, not a personal buy recommendation.